Literature DB >> 26405588

Autocrine signaling of type 1 interferons in successful anticancer chemotherapy.

Erika Vacchelli1, Antonella Sistigu2, Takahiro Yamazaki3, Ilio Vitale4, Laurence Zitvogel5, Guido Kroemer6.   

Abstract

Anthracycline-based chemotherapies are particularly effective if they succeed in reinstating immunosurveillance by the induction of immunogenic cell death (ICD) in the tumor. Recently, we discovered that ICD is coupled to the induction of type 1 interferons (IFNs-I) that act in an autocrine fashion on cancer cells, thereby increasing their immunogenic potential.

Entities:  

Keywords:  IFN; TLR3; cancer; immunogenic chemotherapy; tumor immunity

Year:  2015        PMID： 26405588      PMCID： PMC4570096          DOI： 10.4161/2162402X.2014.988042

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

2.  Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Authors:  Antonella Sistigu; Takahiro Yamazaki; Erika Vacchelli; Kariman Chaba; David P Enot; Julien Adam; Ilio Vitale; Aicha Goubar; Elisa E Baracco; Catarina Remédios; Laetitia Fend; Dalil Hannani; Laetitia Aymeric; Yuting Ma; Mireia Niso-Santano; Oliver Kepp; Joachim L Schultze; Thomas Tüting; Filippo Belardelli; Laura Bracci; Valentina La Sorsa; Giovanna Ziccheddu; Paola Sestili; Francesca Urbani; Mauro Delorenzi; Magali Lacroix-Triki; Virginie Quidville; Rosa Conforti; Jean-Philippe Spano; Lajos Pusztai; Vichnou Poirier-Colame; Suzette Delaloge; Frederique Penault-Llorca; Sylvain Ladoire; Laurent Arnould; Joanna Cyrta; Marie-Charlotte Dessoliers; Alexander Eggermont; Marco E Bianchi; Mikael Pittet; Camilla Engblom; Christina Pfirschke; Xavier Préville; Gilles Uzè; Robert D Schreiber; Melvyn T Chow; Mark J Smyth; Enrico Proietti; Fabrice André; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2014-10-26       Impact factor: 53.440

Review 3.  Immunogenic cell death in cancer therapy.

Authors:  Guido Kroemer; Lorenzo Galluzzi; Oliver Kepp; Laurence Zitvogel
Journal:  Annu Rev Immunol       Date:  2012-11-12       Impact factor: 28.527

Review 4.  Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Mark J Smyth; Guido Kroemer
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

5.  CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy.

Authors:  Yuting Ma; Stephen R Mattarollo; Sandy Adjemian; Heng Yang; Laetitia Aymeric; Dalil Hannani; João Paulo Portela Catani; Helene Duret; Michele W L Teng; Oliver Kepp; Yidan Wang; Antonella Sistigu; Joachim L Schultze; Gautier Stoll; Lorenzo Galluzzi; Laurence Zitvogel; Mark J Smyth; Guido Kroemer
Journal:  Cancer Res       Date:  2013-12-03       Impact factor: 12.701

6.  Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy.

Authors:  Gautier Stoll; David Enot; Bernhard Mlecnik; Jérôme Galon; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2014-02-27       Impact factor: 8.110

7.  Immunogenic cell death inducers as anticancer agents.

Authors:  Oliver Kepp; Laura Senovilla; Guido Kroemer
Journal:  Oncotarget       Date:  2014-07-30

8.  TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR+ head and neck cancer cells.

Authors:  Chwee Ming Lim; Ryan Stephenson; Andres M Salazar; Robert L Ferris
Journal:  Oncoimmunology       Date:  2013-04-29       Impact factor: 8.110

9.  Chemotherapy engages multiple pathways leading to IL-1β production by myeloid leukocytes.

Authors:  Christina Antonopoulos; George R Dubyak
Journal:  Oncoimmunology       Date:  2014-01-03       Impact factor: 8.110

10.  Synthetic induction of immunogenic cell death by genetic stimulation of endoplasmic reticulum stress.

Authors:  Mickaël Michaud; Abdul Qader Sukkurwala; Federica Di Sano; Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal:  Oncoimmunology       Date:  2014-03-25       Impact factor: 8.110
  10 in total
  15 in total

1.  Pro-necrotic molecules impact local immunosurveillance in human breast cancer.

Authors:  Gautier Stoll; Yuting Ma; Heng Yang; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2017-04-17       Impact factor: 8.110

2.  Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

Authors:  Diwakar Davar; Hong Wang; Joe-Marc Chauvin; Ornella Pagliano; Julien J Fourcade; Mignane Ka; Carmine Menna; Amy Rose; Cindy Sander; Amir A Borhani; Arivarasan Karunamurthy; Ahmad A Tarhini; Hussein A Tawbi; Qing Zhao; Blanca H Moreno; Scott Ebbinghaus; Nageatte Ibrahim; John M Kirkwood; Hassane M Zarour
Journal:  J Clin Oncol       Date:  2018-10-25       Impact factor: 44.544

3.  Contribution of annexin A1 to anticancer immunosurveillance.

Authors:  Elisa Elena Baracco; Gautier Stoll; Peter Van Endert; Laurence Zitvogel; Erika Vacchelli; Guido Kroemer
Journal:  Oncoimmunology       Date:  2019-08-14       Impact factor: 8.110

4.  Activating a collaborative innate-adaptive immune response to control metastasis.

Authors:  Lijuan Sun; Tim Kees; Ana Santos Almeida; Bodu Liu; Xue-Yan He; David Ng; Xiao Han; David L Spector; Iain A McNeish; Phyllis Gimotty; Sylvia Adams; Mikala Egeblad
Journal:  Cancer Cell       Date:  2021-09-02       Impact factor: 38.585

5.  Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.

Authors:  Annamaria Gulla; Eugenio Morelli; Mehmet K Samur; Cirino Botta; Teru Hideshima; Giada Bianchi; Mariateresa Fulciniti; Stefano Malvestiti; Rao H Prabhala; Srikanth Talluri; Kenneth Wen; Yu-Tzu Tai; Paul G Richardson; Dharminder Chauhan; Tomasz Sewastianik; Ruben D Carrasco; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood Cancer Discov       Date:  2021-04-23

Review 6.  Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death.

Authors:  Zahra Asadzadeh; Elham Safarzadeh; Sahar Safaei; Ali Baradaran; Ali Mohammadi; Khalil Hajiasgharzadeh; Afshin Derakhshani; Antonella Argentiero; Nicola Silvestris; Behzad Baradaran
Journal:  Cancers (Basel)       Date:  2020-04-23       Impact factor: 6.639

7.  Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response.

Authors:  Camilla Salvagno; Metamia Ciampricotti; Sander Tuit; Cheei-Sing Hau; Antoinette van Weverwijk; Seth B Coffelt; Kelly Kersten; Kim Vrijland; Kevin Kos; Thomas Ulas; Ji-Ying Song; Chia-Huey Ooi; Dominik Rüttinger; Philippe A Cassier; Jos Jonkers; Joachim L Schultze; Carola H Ries; Karin E de Visser
Journal:  Nat Cell Biol       Date:  2019-03-18       Impact factor: 28.824

8.  Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells.

Authors:  Maxine Bauzon; Penelope M Drake; Robyn M Barfield; Brandon M Cornali; Igor Rupniewski; David Rabuka
Journal:  Oncoimmunology       Date:  2019-01-22       Impact factor: 8.110

9.  Hypoxia Induces Transcriptional and Translational Downregulation of the Type I IFN Pathway in Multiple Cancer Cell Types.

Authors:  Ana Miar; Esther Arnaiz; Esther Bridges; Shaunna Beedie; Adam P Cribbs; Damien J Downes; Robert A Beagrie; Jan Rehwinkel; Adrian L Harris
Journal:  Cancer Res       Date:  2020-10-28       Impact factor: 13.312

Review 10.  Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance.

Authors:  Megha Budhwani; Roberta Mazzieri; Riccardo Dolcetti
Journal:  Front Oncol       Date:  2018-08-21       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.